Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Patients With Extensive Stage Small-Cell Lung Cancer

NCT05245994 is registered in ClinicalTrials.gov with Li Zhang, MD as lead sponsor.

NCT NCT05245994
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05245994 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Patients With Extensive Stage Small-Cell Lung Cancer
Lead sponsor
Li Zhang, MD
Phase
Phase 2
Overall status
Unknown status
Start date
August 21, 2021
Completion date
November 30, 2023
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

durvalumab, lung cancer, small cell lung cancer